Cargando...
Combination of Bevacizumab, Irinotecan and Temozolomide for Refractory or Relapsed Neuroblastoma: Results of a Phase II Study
BACKGROUND: The rationale for studying the combination of bevacizumab, irinotecan and temozolomide (BIT) in neuroblastoma is based on: (a) vascular endothelial growth factor (VEGF) expression is associated with an aggressive phenotype, (b) anti-VEGF antibody bevacizumab enhances irinotecan-mediated...
Gardado en:
| Publicado en: | Pediatr Blood Cancer |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
2017
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5555116/ https://ncbi.nlm.nih.gov/pubmed/28111925 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/pbc.26448 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|